

**TERMINAL DISCLAIMER TO OBTAIN A PROVISIONAL DOUBLE
PATENTING REJECTION OVER PENDING SECOND, THIRD, FOURTH,
FIFTH, SIXTH AND SEVENTH APPLICATIONS**Docket No.
(Optional)
4001.003000

In re Application of: Philip E. Thorpe and Sophia Ran

Application No.: 10/621,269

Filed: July 15, 2003

For: Selected Antibody Compositions For Binding To Aminophospholipids (As Amended)


Petitioner, Board of Regents, The University of Texas System, is the owner of the entire interest in the instant application. Petitioner hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending second Application Serial No. 10/642,124, filed on August 15, 2003; pending third Application Serial No. 10/642,122, filed on August 15, 2003; pending fourth Application Serial No. 10/642,060, filed on August 15, 2003; pending fifth Application Serial No. 10/642,099, filed on August 15, 2003; pending sixth Application Serial No. 10/642,064, filed on August 15, 2003; and pending seventh Application Serial No. 10/642,118, filed on August 15, 2003. Petitioner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second, third, fourth, fifth, sixth and seventh applications are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of any patent granted on the second, third, fourth, fifth, sixth and seventh applications, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Pursuant to 37 C.F.R. § 3.73, the undersigned has reviewed the evidentiary documents, specifically, the Assignment of the instant application to Board of Regents, The University of Texas System, which has been recorded at Reel 015258/Frame 0618, and certifies that, to the best of his or her knowledge and belief, title of the instant application is in the name of Assignee, Board of Regents, The University of Texas System.

For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned (whose title is supplied below) is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

October 3, 2006
DateBy: 
Shelley P.M. Bussey, Reg. No. 39,458
Agent for Applicants

☒ Terminal disclaimer fee under 37 C.F.R. § 1.20(d) should be deducted from Peregrine Pharmaceuticals, Inc. Deposit Account No. 50-3493/4001.003000.

☒ PTO suggested wording for terminal disclaimer was:

☐ unchanged. ☒ changed (if changed, an explanation should be supplied).

Paragraph in bold added for compliance with 37 C.F.R. § 3.73

10621269

503493

00000004

ZIHAR1

10/18/2006

65.00 DA

01 FC:2814